Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 3 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Recs

0
Player Avatar pchop123 (79.53) Submitted: 10/15/2012 10:16:52 AM : Outperform Start Price: $6.90 CYCC Score: -18.38

still has great legs for an upside run

Featured Broker Partners


Advertisement